Anthrax Vaccine Adsorbed

Anthrax Vaccine Adsorbed
Name	Anthrax Vaccine Adsorbed
Type	vaccine
Target	Anthrax
Tradename	Biothrax
Administered	Intramuscular
Legal status	Approved in United States for certain uses

Anthrax Vaccine Adsorbed is a licensed prophylactic vaccine developed to reduce risk from infection by Bacillus anthracis. It has been used in public health, occupational medicine, and biodefense contexts involving agencies such as the Centers for Disease Control and Prevention, the Department of Defense, and the Food and Drug Administration. Deployment decisions have involved coordination among organizations including the World Health Organization, the National Institutes of Health, the Centers for Medicare & Medicaid Services, and international partners such as the European Medicines Agency.

Medical uses

Anthrax Vaccine Adsorbed is indicated for prevention of disease following exposure related to industrial risks at facilities like United States Army Medical Research Institute of Infectious Diseases sites, workplace incidents at companies like Merck partner facilities, and potential incidents involving groups such as Al Qaeda-related threats. It is used in pre-exposure immunization programs for personnel at high risk, including members of the United States Army and contractors working with select agent labs affiliated with the National Institutes of Health and Centers for Disease Control and Prevention. Post-exposure prophylaxis decisions involve coordination with agencies such as Department of Health and Human Services, military commands like United States Central Command, and international public health authorities including World Health Organization regional offices.

Composition and formulation

The vaccine is an adsorbed preparation derived from a cell-free filtrate of an avirulent strain of Bacillus anthracis produced under Good Manufacturing Practice standards overseen by agencies like the Food and Drug Administration and quality auditors from organizations such as International Organization for Standardization. The formulation includes an aluminum-based adjuvant similar to adjuvants evaluated by researchers at institutions such as Johns Hopkins University and Harvard Medical School. Manufacturing processes have involved contractors with experience in biologics used by entities like Merck and regulatory submissions to agencies including the European Medicines Agency and the Therapeutic Goods Administration.

Mechanism of action

Protection is mediated primarily by induction of antibodies targeting the protective antigen component of Bacillus anthracis toxins, a mechanism characterized in studies from research centers like Rocky Mountain Laboratories, Walter Reed Army Institute of Research, and laboratories affiliated with Pasteur Institute. Neutralizing antibodies interfere with toxin binding and entry pathways described in literature from investigators at Stanford University, Massachusetts Institute of Technology, and University of Oxford. Cellular responses studied by teams at Imperial College London and Scripps Research complement humoral immunity, and correlates of protection have been modeled by researchers at Johns Hopkins Bloomberg School of Public Health and London School of Hygiene & Tropical Medicine.

Administration and dosing

Recommended schedules approved by the Food and Drug Administration and employed by the United States Army include a multi-dose series administered intramuscularly with booster doses; programmatic guidance has been issued by institutions such as the Advisory Committee on Immunization Practices and the Department of Defense. Clinical trial protocols were conducted at sites including Walter Reed National Military Medical Center, Baylor College of Medicine, and University of Pennsylvania medical centers. Occupational health programs in industries regulated by agencies like the Occupational Safety and Health Administration adapt dosing algorithms to exposure risk assessments performed by organizations such as Occupational Safety and Health Administration consultants and hospital occupational health services at centers like Mayo Clinic.

Safety and adverse effects

Safety profiles have been evaluated in randomized and observational studies published by investigators at Harvard Medical School, Brigham and Women's Hospital, and epidemiologists from the Centers for Disease Control and Prevention. Reported local reactions mirror those characterized in literature from Cleveland Clinic and Johns Hopkins Hospital researchers, while systemic effects have been monitored in cohorts from University of Michigan and University of California, San Diego. Surveillance systems managed by the Vaccine Adverse Event Reporting System and analyses from the Institute of Medicine have informed benefit–risk assessments used by policymakers at Department of Defense and public health agencies like Public Health England.

Manufacturing and regulatory status

Manufacturing occurs under contract and facility oversight consistent with standards enforced by the Food and Drug Administration and licensing frameworks used by the European Medicines Agency. Licensure, lot release, and post-marketing surveillance involve regulatory science collaborations seen between the National Institutes of Health and industry partners such as Emergent BioSolutions and formerly BioPort Corporation. Export and distribution logistics have involved coordination with agencies including the Department of Health and Human Services and international regulatory authorities in countries such as Canada and members of the European Union.

History and controversy

Development and deployment trace back to programs initiated in response to historical biological threats assessed by commissions including the Gore Commission and studies at USAMRIID. Controversies over mandates and safety were litigated and debated among stakeholders including veterans' organizations such as the American Legion, advocacy groups like Public Citizen, and oversight bodies such as the Government Accountability Office. Policy disputes engaged elected officials in the United States Congress, hearings before committees like the Senate Armed Services Committee, and review by panels convened by the Institute of Medicine and academic investigators at institutions such as Yale University and Columbia University.

Category:Vaccines